Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02…
Parker Waichman Applauds Health Canada and Australia for Strengthening NAION Safety Guidance for Certain GLP-1 Medications
Canada now directs physicians to urgently evaluate sudden vision loss and discontinue Ozempic and Mounjaro if NAION is…
Franchise Equity Partners Acquires Bravo Fit, Planet Fitness’ Australian Franchisee
Investment Advances Planet Fitness’ Commitment to Providing Accessible and Affordable Fitness Internationally and Targets Over 135 Planet Fitness…
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
Mississauga, ON, July 15, 2026 /PRNewswire/ – Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare…
Planet DDS and Truro Bring Predictive Intelligence to the Denticon Ecosystem: Transforming Patient-Facing Dental Operations for Capacity and Revenue Optimization
“I’m incredibly excited about our partnership with Truro AI because it solves a problem that has frustrated dental…
Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes
Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach…
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney…
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use NEW…
Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®
MISSISSAUGA, ON, May 26, 2026 /CNW/ – Novo Nordisk Canada is announcing that effective Friday, May 29, 2026,…
Vi Launches Suite of AI Agents for Healthcare, Life Sciences, and Wellness Enterprises; Completes $145M Transaction at $1.64B Valuation
NEW YORK, May 19, 2026 /PRNewswire/ — Vi, the enterprise-AI platform for health, today announced a new suite…
Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
TORONTO, May 14, 2026 /PRNewswire/ – Apotex Inc. (“Apotex” or the “Company”), the largest Canadian‑based global health company,…